# OnCo record novartis-glivec-ruling (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/novartis-glivec-ruling/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "novartis-glivec-ruling" ;
  schema:name "Novartis v. Union of India (Glivec, 2013)"@en ;
  schema:alternateName "Novartis v Union of India"@en, "Glivec case"@en, "Glivec ruling"@en, "Gleevec case India"@en, "section 3(d)"@en, "Section 3(d) Patents Act"@en, "evergreening"@en ;
  schema:description "In April 2013 India's Supreme Court refused Novartis a patent on the crystal form of imatinib used in Glivec, ruling that a new form of a known drug must show improved therapeutic effect, a decision that kept Indian generics of the leukaemia drug legal and became the model for anti-evergreening laws elsewhere."@en ;
  schema:url <https://onco.cc/terms/novartis-glivec-ruling/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Novartis_v._Union_of_India_%26_Others> ;
  schema:citation <https://en.wikipedia.org/wiki/Novartis_v._Union_of_India_%26_Others> ;
  onco:tag "law", "in" ;
  onco:related <https://onco.cc/terms/nexavar-compulsory-licence/>, <https://onco.cc/terms/trips-doha/>, <https://onco.cc/terms/hatch-waxman/>, <https://onco.cc/terms/india-new-drugs-rules-2019/>, <https://onco.cc/terms/us-regulatory-exclusivity/>, <https://onco.cc/technologies/global-oncology-access/>, <https://onco.cc/terms/drug-price-transparency/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-ip-collaboration/> .